INTRODUCTION
Rheumatoid arthritis is an autoimmune disease with a worldwide prevalence of approximately 0.5 to 1% among adults, 1 and two to three times more common in women compared with men. In India, the prevalence in adults has been estimated to be 0.75% 2 mainly affecting articular and extra-articular structures resulting in pain, disability, and mortality 3 leading to erosive joint damage and functional impairment. 4 The signs and symptoms of RA can be correlated with sign and symptoms of Amavata. The pathogenesis of Amavata revolves around Ama and Vata. Ama is formed due to malfunctioning of the digestive and metabolic mechanisms, initiated by Viruddha Ahara-Vihar with pre-existence of Mandagni. 5 The manifestation of the symptoms in Amavata is due to Vata and Ama, but Kapha
JRAS
and Pitta may also invariably be involved in its samprapti (pathogenesis). 6 Ayurveda, an ancient traditional medicine system, is widely practiced throughout the country. It is reported that 60 to 90% of persons with arthritic conditions use complementary and alternative medicines. 7 People from all over world are also developing interest in traditional herbal practices. The concern about safety, ADRs, and drug-drug interactions with these traditional health care systems is rising. 8 This set of studies was done to analyze the safety of Simhanada Guggulu, Brihat Saindhavadya Taila, Vatari Guggulu, Rasna Saptaka Kashaya, and Hingvashtaka Churna in patients with RA.
DRUG PROFILE
The different formulations are chosen as per the etiology and hence the ingredients of these indicated formulations have multifarious actions. The major ingredients reduce the Amavastha to Niramavastha by improving Agni (digestive fire) and pacifying the vitiated Vata dosha.
Major ingredients of these indicated formulations are Vatashamaka (pacifing Vata), Amapachaka (eliminating undigested metabolic products), Ama Shoshaka (drying undigested metabolic products), Deepniya (potentiating digestive activity), and possess Ushna (hot) Virya and Katu (pungent) Vipaka properties (Table 1) .
OBJECTIVE
Critical analysis and presentation of clinical safety outcomes of classical Ayurvedic formulations Simhanada Guggulu, Brihat Saindhavadi Taila, Vatari Guggulu, Rasna Saptaka Kashaya, and Hingvashtaka Churna in patients of RA were generated through multicenter open label studies at different CCRAS institutes.
MATERIALS AND METHODS
The formulations fulfilling the physicochemical standards and quality parameters were prepared as per standard operating procedures and procured from good manufacturing practice-certified companies for all the studies. Table 2 . Follow-up was done every 2 weeks to record the onset of any ADRs during the intervention. The data thus generated were analyzed to evaluate the safety of these formulations in patients with RA.
Statistical Analysis
Laboratory parameters at the beginning and at the end of the trial period were compared using paired t-test. A p-value of <0.05 was considered significant. All statistical analyses were performed using Statistical Package for Social Sciences, version 15.0.
OBSERVATION

Study I: Effect of Simhanada Guggulu and Brihat Saindhavadya Taila
Total 111 subjects completed the trial. The majority of the subjects were females, i.e., 96 (86.5%). Total 28 (25.2%) were illiterate and 83 (74.8%) know how to read and write. Thirty-one (27.9%) belonged to below poverty line, and 11 (9.9%) were vegetarian and 100 (90.1%) were nonvegetarian. It was also observed that maximum number of subjects 48 (43.2%) were of Vata-Pittaja prakriti followed by 24 (21.6%) Pitta-Kaphaja prakriti. Table 3 shows the basic information and demographic profile of the subjects. The combination of Simhanada Guggulu and Brihat Saindhavadya Taila has been found effective in the management of RA. Pain in joints, swelling in joints, morning stiffness and tenderness, along with malaise and fever were the major symptoms seen, which were assessed on disease activity score (DAS) and Disability Index. The clinical improvement was significant. The DAS and Disability Index baseline mean was 6.8162 and it reduced to 5.0715 on 84th day. Serum bilirubin, serum glutamic pyruvic transaminase (SGPT), serum glutamic oxaloacetic transaminase (SGOT), serum alkaline phosphatase, serum protein, albumin, globulin, blood urea, and serum creatinine were within normal limits during the entire period and the values were compared with paired t-test after the trial and there was no detectable change in these parameters (Table 4 and Graphs 1 to 4).
Study II: Effect of Vatari Guggulu, Rasna Saptaka Kashaya and Brihat Saindhavadya Taila
Total 225 subjects completed the trial. The majority of the subjects were females, i.e., 182 (80.88%). Total 35 Table 3 shows the basic information and demographic profile of the subjects. The combination of Vatari Guggulu, Rasna Saptaka Kashaya, and Brihat Saindhavadya Taila has been found effective in the management of RA. Pain in joints, swelling in joints, morning stiffness and tenderness, along with malaise and fever were the major symptoms seen, which were assessed on DAS and Disability Index. The clinical improvement was significant. The effect of this treatment on LFTs and KFTs was assessed at baseline and at 84th day. The values were within range during the entire trial period (Table 4 and Graphs 1 to 4). These observations validate that these classical drugs are safe for human use. Further, no adverse drug effect or AEs were reported during the treatment period.
Study 3: Effect of Vatari Guggulu, Hingvashtaka Churna, and Brihat Saindhavadya Taila
Total 179 subjects completed the trial. The majority of the subjects were females, i.e., 156 (87.2%). Thirty (16.8%) were illiterate and 149 (83.2%) were literate. Thirty-six (20.1%) belonged to below poverty line and 143 (79.9%) belonged to above poverty line. About 32 (17.9%) were vegetarian and 147 (82.1%) were nonvegetarian. It was also observed that maximum number of subjects (85 (47.5%)) were of Pitta-Kaphaja prakriti and 64 (35.8%) were of Vata Pittaja prakriti. Table 3 shows the basic information and demographic profile of the subjects. The combination of Vatari Guggulu, Hingvashtaka Churna, and Brihat Saindhavadya Taila has been found effective in the management of RA. Pain in joints, swelling in joints, morning stiffness and tenderness, along with malaise and fever were the major symptom seen which were assessed on DAS and Disability Index. The clinical improvement was significant. The effect of this treatment on LFTs and KFTs was assessed at baseline and at 84th day. The values were within range during the entire trial period (Table 4 and Graphs 1 to 4). These observations validate that these classical drugs are safe for human use. Further, no adverse drug effect or AEs were reported during the treatment period. The data regarding demographic profile, efficacy, and safety obtained from the all three studies are given in Tables 3, 4 and Graphs 1 to 4.
DISCUSSION
The main purpose was to collect the data from three different clinical studies executed in peripheral institutes of CCRAS to assess the safety profile of 5 formulations viz., Simhanada Guggulu, Vatari Guggulu, Hingvashtaka Churna, Rasna Saptaka Kashaya and Brihat-Saindhavadya Taila through liver function tests and kidney function tests. In these studies though there was change in LFT and KFT before and after the Ayurvedic interventions but the change was not to that extent that could cross the normal limit. During these studies none of the patients complained of any adverse reaction or side effects. Simhanada Guggulu, Brihat Saindhavadya Taila, Vatari Guggulu, Rasna Saptaka Kashaya, and Hingvashtaka Churna have been studied in the management of RA. Joint pain, swelling, tenderness, morning stiffness, fever, malaise, fatigue, and weakness are the major clinical manifestations in this disease. The aforementioned clinical studies demonstrate that the scheduled Ayurvedic treatment has potential effects to manage these signs and symptoms without any adverse effect. There is highly significant progress in DAS-28, Disability Index score, 36-item Short Form Health Survey (SF-36) survey compared with the baseline and 84th day as well was 112th day of follow-up in statistical analysis. All parameters show statistically highly significant results.
These 15 It is also proved by latest researches that ginger has anti-inflammatory activity and some of the constituents are potent inhibitors of prostaglandin synthesis and leukotriene synthesis. 16 Simhanada Guggulu and Vatari
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Guggulu have Guggulu as main ingredient. Both formulations are used as antiinflammatory drugs. This effect is probably due to guggulsterones present in both drugs. Guggulsterone is reported to inhibit significantly lipopolysaccharide-induced upregulation of tumor necrosis factor-alpha expression and cyclooxygenase-2 production. 17 When Brihat Saindhavadya Taila was applied locally the local counter irritant effect occurred and diluted the accumulated Doshas. Due to Ushna Tikshna property, it acts as Shamaka of vitiated Ama and Vata. All these three studies scheduled for Ayurvedic treatment have potential effects to manage signs and symptoms of RA. Statistical analysis shows that there is highly significant increase in DAS-28, Disability Index score, SF-36 survey compared with the baseline and 84th day as well as 112th day of follow-up. Serum bilirubin, SGPT, SGOT, serum alkaline phosphatase, serum protein, albumin, globulin, blood urea, and serum creatinine were within normal limits during the entire period and the values were compared with paired t-test after the trial and there was no detectable change in these parameters. This study revealed that all the parameters were within the specified limits during the entire period.
CONCLUSION
The study to evaluate the safety and efficacy of Simhanada Guggulu, Brihat Saindhavadya Taila, Vatari Guggulu, Rasna Saptaka Kashaya, and Hingvashtaka Churna was conducted at peripheral institutes of CCRAS spread throughout various bio-geographical areas of India. The analysis of outcome of these scientifically planned studies demonstrates that in spite of the differences in gender, socioeconomic status, age group, prakrati, and geographic region Simhanada Guggulu, Brihat Saindhavadya Taila, Vatari Guggulu, Rasna Saptaka Kashaya, and Hingvashtaka Churna proved to be very safe, effective, and tolerable in the management of RA. No ADRs or AEs pertaining to drug interaction were noticed during the trial period. This study ascertains that the classical Ayurvedic formulations are safer as far as liver and renal functions are concerned. The data collected from these three studies provide a positive conclusion about the safety of these Ayurvedic medicines. Further exploration with larger samples can be taken to establish the safety concern.
